DaVita HealthCare Partners Inc
$ 148.13
2.46%
16 Apr - close price
- Market Cap 9,902,343,000 USD
- Current Price $ 148.13
- High / Low $ 148.79 / 145.02
- Stock P/E 15.58
- Book Value -9.50
- EPS 9.51
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.65 %
- 52 Week High 159.42
- 52 Week Low 101.00
About
DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.
Analyst Target Price
$151.71
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-18 | 2025-10-28 | 2025-08-05 | 2025-05-12 | 2025-02-13 | 2024-10-29 | 2024-08-06 | 2024-05-02 | 2024-02-13 | 2023-11-07 | 2023-08-03 | 2023-05-08 |
| Reported EPS | 3.4 | 2.51 | 2.95 | 2 | 2.24 | 2.59 | 2.5 | 2.26 | 1.62 | 2.62 | 1.91 | 1.25 |
| Estimated EPS | 3.1 | 3.18 | 2.75 | 2.02 | 2.13 | 2.72 | 2.54 | 1.95 | 1.59 | 2.02 | 1.69 | 1.15 |
| Surprise | 0.3 | -0.67 | 0.2 | -0.02 | 0.11 | -0.13 | -0.04 | 0.31 | 0.03 | 0.6 | 0.22 | 0.1 |
| Surprise Percentage | 9.6774% | -21.0692% | 7.2727% | -0.9901% | 5.1643% | -4.7794% | -1.5748% | 15.8974% | 1.8868% | 29.703% | 13.0178% | 8.6957% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 2.41 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DVA
2026-04-17 10:10:16
This article analyzes Cigna (CI) after recent share price fluctuations, finding it undervalued according to Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) models. The DCF analysis suggests a 69.0% discount compared to its intrinsic value of $891.23 per share, while its P/E ratio of 12.23x is below both the industry average and Simply Wall St's Fair Ratio of 29.65x, signaling potential value after a 14.5% decline over the past year.
2026-04-16 17:18:00
DaVita Inc. (DVA) saw its stock rise by 2.46% to $148.13 on Thursday, outperforming the broader market. This gain snapped a two-day losing streak for the company. The S&P 500 Index and the Dow Jones Industrial Average also recorded modest gains on the same day.
2026-04-15 22:21:30
DaVita Inc (DVA) shares recently fell 3.3% but are considered "Modestly Undervalued" by GuruFocus, with a GF Value™ of $161.62 against a current price of $144.57. The company boasts a strong GF Score™ of 92/100, driven by high profitability and growth, yet shows weakness in financial strength and significant insider selling. Investors are advised to weigh these factors before making decisions.
2026-04-15 17:18:00
Shares of DaVita Inc. (DVA) fell 3.27% to $144.57 on Wednesday, marking its second consecutive day of losses. This underperformance occurred on a mixed trading day, with the S&P 500 Index rising and the Dow Jones Industrial Average falling. The article highlights DaVita's stock performance relative to the broader market.
2026-04-15 16:07:34
DaVita Inc. is positioned for reliable investor returns due to its dominant role in the U.S. kidney care market, driven by an aging population and increasing rates of chronic kidney disease. The company's vertically integrated dialysis business model, extensive network of centers, and focus on operational efficiency provide stable cash flows, largely insulated from economic cycles. Analysts generally view DaVita as a defensive healthcare play with upside potential from volume growth and strategic initiatives like home dialysis.
2026-04-15 04:06:31
DaVita Inc. is positioned for reliable revenue due to its dominant role in kidney care, especially with an aging U.S. population increasing dialysis needs. The company's vertically integrated business model, largely focused on U.S. operations and reimbursed by government programs, provides stable cash flows. While analysts view DaVita positively as a defensive healthcare stock with growth potential from volume, investors should consider risks like labor costs, regulatory scrutiny, and competitive pressures.
